Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2009-11-11
pubmed:abstractText
Mesenchymal stromal cells (MSC) have been thought to be attractive candidates for the treatment of Duchenne muscular dystrophy (DMD), but the rate of MSC myogenesis is very low. Thus MSC treatment for DMD is restricted. Myostatin (Mstn), a negative regulator of myogenesis, is known to be responsible for limiting skeletal muscle regeneration. We hypothesized that inhibition of Mstn by using anti-Mstn antibody (Ab) would ameliorate the myogenic differentiation of MSC in vitro and in vivo.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1477-2566
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
849-63
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Inhibition of myostatin promotes myogenic differentiation of rat bone marrow-derived mesenchymal stromal cells.
pubmed:affiliation
Neurology Department, The First Affiliated Hospital, Sun Yat-Sen University, Guang Zhou, PR China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't